GenSight Biologics S.A.
GenSight Biologics S.A. (GSGTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gsgtf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for GenSight Biologics S.A. (GSGTF) measures how much investors pay for each dollar of the company's trailing earnings. GSGTF's current PE ratio of N/A is calculated by dividing its stock price of $0.19 by its TTM earnings per share of -$0.06.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
GenSight Biologics S.A.You GSGTF | $31M | N/A | — | -$0.06 |
 Allergy Therapeutics plc AGYTF | $655M | N/A | — | -$0.01 |
 Avacta Group Plc AVCTF | $437M | N/A | — | -$0.10 |
 Beijing Tong Ren Tang Chinese Medicine Company Limited BJTRF | $536M | 10.64x | -17.8% | $0.47 |
 BioInvent International AB (publ) BOVNF | $436M | N/A | — | -$5.05 |
 Basilea Pharmaceutica AG BPMUF | $806M | 15.24x | +17.8% | $3.29 |
 Healios K.K. HLOSF | $291M | N/A | — | -$20.61 |
Industry Average 2 peers with valid PE | — | 12.94x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.08 | — | |
2024-12-31 FY2024 | — | $-0.17 | — | |
2023-12-31 FY2023 | — | $-0.54 | — | |
2022-12-31 FY2022 | — | $-0.60 | — | |
2021-12-31 FY2021 | — | $-0.63 | — | |
2020-12-31 FY2020 | — | $-0.97 | — | |
2019-12-31 FY2019 | — | $-1.08 | — | |
2018-12-31 FY2018 | — | $-1.37 | — | |
2017-12-31 FY2017 | — | $-1.10 | — | |
2016-12-31 FY2016 | — | $-1.36 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for GenSight Biologics S.A. (GSGTF) measures how much investors pay for each dollar of the company's trailing earnings. GSGTF's current PE ratio of N/A is calculated by dividing its stock price of $0.19 by its TTM earnings per share of -$0.06.
Frequently asked questions
GSGTF pe ratio · 6 questionsGSGTF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.19 and TTM EPS of -$0.06. Data sourced from Financial Modeling Prep via GSGTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GenSight Biologics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09